Spondyloarthritis & psoriatic arthritis

Late‐Onset Spondyloarthritis Presenting as Glucocorticoid‐Resistant Polymyalgia Rheumatica: A Hitherto Underappreciated Entity in Which Tumor Necrosis Factor or Interleukin ‐17 Blockade May Have a Therapeutic Role

Arthritis RheumatolPublished Retrospective case series

Authors' conclusion

Late-onset SpA with PMR clinical presentations is characterized by failure to respond to or taper GC therapy and is often identified by SpA-specific osteitis patterns on MRI.

Study context

Population
Patients at Leeds Teaching Hospitals NHS Trust with psoriatic arthritis (PsA) or axSpA initially diagnosed as polymyalgia rheumatica (PMR) (2002–2024), fulfilling 2012 EULAR/ACR or Bird et al PMR criteria17 women and 14 men
Participants
31 patients
Outcome
Clinical and imaging features of SpA initially diagnosed as PMR
Methodological detailssingle-centre
  • Single-centre

Main finding

As reported in the abstract

Median age, years (IQR 58-69)
62
Spondyloarthritis (SpA) diagnosis within 3 months of presentation
12
SpA diagnosis during remaining follow-up (median 3 [IQR 1-4] years)
19
HLA-B27 positive, of 27 tested
4
Bone marrow edema (BME) on magnetic resonance imaging (MRI) in spine and/or sacroiliac joints, of 25 imaged
20 (80%)
BME in sacroiliac joint
17 (68%)
BME in spine
15 (60%)
Clinical resolution with C-reactive protein (CRP) normalization after initial glucocorticoid (GC), of 31
21
Flares or CRP elevations among 21 initial responders
7
Disease-modifying antirheumatic drugs (DMARDs) used, of 31
21
csDMARDs
8
Biologic agents (8 TNFi, 3 IL-17i)
11
Treated with ≤10 mg/day GC
10

Observational data: associations, not effects.

Original publication

Late‐Onset Spondyloarthritis Presenting as Glucocorticoid‐Resistant Polymyalgia Rheumatica: A Hitherto Underappreciated Entity in Which Tumor Necrosis Factor or Interleukin ‐17 Blockade May Have a Therapeutic Role. Arthritis Rheumatol. Published 8 December 2025. doi:10.1002/art.43320

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.